NRx Pharmaceuticals announced submission an investigational new drug, or IND, application to the FDA for the use of NRX-101 to treat Chronic Pain. The IND application leverages pioneering research on the use of D-cycloserine in the treatment of chronic pain and the recent licensure by NRx of a US Patent for the use of D-cycloserine in the treatment of pain. Nonclinical and substantial clinical data are already on file with FDA for NRX-101, which has already been granted Breakthrough Therapy Designation for the treatment of suicidal Bipolar Depression.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRXP:
- NRx Pharmaceuticals to purchase 3M shares of preferred stock at 40c per share
- NRx Pharmaceuticals reports Q2 EPS (12c), consensus (14c)
- NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
- Nrx Pharmaceuticals, Inc. (NRXP) Q2 Earnings Cheat Sheet
- NRx Pharmaceuticals signs license agreement for D-cycloserine patent claim